Condition: Migraine · Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
This description comes directly from the study's public registry record.
Ana Beatriz Gago Veiga · +34 915202416 · anabeatriz.gago@salud.madrid.org
Iris Fernández Lázaro · irisfdezlaz@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital Clínico Universitario Lozano Blesa | Zaragoza, Aragon, Spain | Recruiting |
| Hospital Universitario Donostia | Donostia / San Sebastian, Basque Country, Spain | Recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander, Cantabria, Spain | Recruiting |
| Hospital Clínico Universitario de Valladolid | Valladolid, Castille and León, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron Research Institute | Barcelona, Catalonia, Spain | Recruiting |
| Hospital Universitario de La Princesa | Madrid, Madrid, Spain | Recruiting |
| Hospital Universitario Politécnico La Fe | Valencia, Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06459648